Arovella Therapeutics Ltd (ASX:ALA) and its collaboration partners from the Imperial College London have presented data using ALA’s CAR-iNKT cell therapy platform in a poster at the 65th Annual American Society for Hematology (ASH) conference in San Diego, California.
The data uses ALA’s proprietary CAR-iNKT platform, which Professor Karadimitris of Imperial London College pioneered.
The poster, presented by Dr Kanagaraju Ponnusamy, describes the use of the platform to produce CAR-iNKT cells targeting B-cell maturation antigen (BCMA) to eliminate Multiple Myeloma and describes the optimisation of the CAR construct.
Promising cell platform
“It is excellent to see the additional data using the CAR-iNKT cell platform,” Arovella Therapeutics managing director and CEO Dr Michael Baker said.
“We firmly believe in the platform's potential and this data highlights there are avenues to expand the use of the platform in multiple tumour types.
“To have this accepted and presented at ASH is a testament to the exciting research that continues at Imperial College London and the promise of the iNKT cell platform.”
Dr Baker spoke with Professor Karadimitris about the data in an interview available on the company’s Youtube channel.
The company says the data “highlights the potential of the iNKT cell platform and demonstrates its broad applicability across multiple tumour types by incorporating different CARs”.